Hvivo
18
2
2
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 18 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
50%
8 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain
Role: lead
Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5)
Role: lead
Longitudinal Phenotyping and Endotyping Study in Adult Patients With Mild, Moderate, or Severe Asthma
Role: lead
SARS-CoV-2 Human Challenge Characterisation Study
Role: collaborator
Study of SAB-176 in Healthy Adult Participants
Role: collaborator
COVID-19 SARS-CoV-2 Screening Protocol
Role: collaborator
Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults
Role: lead
Dose, Safety, and Pathogenicity of a New Influenza B Strain
Role: lead
Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain
Role: lead
Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine
Role: collaborator
Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model
Role: lead
Study Examining PrEP-001 in Healthy Subjects
Role: lead
RSV Study in Adults 60 to 75 Years of Age
Role: lead
A Study to Examine the Duration of Effect of PrEP-001 in Healthy Subjects Challenged With HRV-16
Role: collaborator
Study Examining PrEP-001 in Subjects With Asthma
Role: lead
Influenza Challenge Study in Healthy Volunteers
Role: lead
Discovering New Treatments for Asthma and COPD. A New Human Rhinvovirus for Human Challenge
Role: lead
Development of an Intranasal Proteosome Influenza Vaccine
Role: lead
All 18 trials loaded